Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
Patient took the first Vivotif capsule and doxycycline on the same day; Case reference number US-BN-2025-001340 is a spontaneous case initially received from a pharmacist via Communications (reference number: USBAV25-1887) on 01-Aug-2025 and concerns a male patient of unspecified age. The patient's medical history was not provided. The patient's concomitant medications included doxycycline for acne. The patient's concurrent medical history included acne. On 30-Jul-2025, the patient took the morning dose of Doxycycline and unknown of time after Doxycycline, also reported as on the same day, the patient took the first Vivotif capsule (batch number: unknown) at an unknown dose, orally, for an unknown indication (explicitly coded as 'labelled drug-drug interaction medication error'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No additional information was provided.; Reporter's Comments: A male patient of unspecified age took the morning dose of Doxycycline and unknown of time after Doxycycline, also reported as on the same day, the patient took the first Vivotif capsule for an unknown indication, which is considered as labelled drug-drug interaction medication error. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Labelled drug-drug interaction medication error is considered as listed per company convention. The patient's medical history was not provided, concomitant medications included doxycycline for acne, and concurrent medical history included acne. Labelled drug-drug interaction medication error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age took the morning dose of Doxycycline and unknown of time after Doxycycline, also reported as on the same day, the patient took the first Vivotif capsule for an unknown indication, which is considered as labelled drug-drug interaction medication error. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Labelled drug-drug interaction medication error is considered as listed per company convention. The patient's medical history was not provided, concomitant medications included doxycycline for acne, and concurrent medical history included acne. Labelled drug-drug interaction medication error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Acne
DOXYCYCLINE